Pfizer-BioNTech study supports 97% effectiveness of COVID-19 vaccine

By The Science Advisory Board staff writers

March 11, 2021 -- Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 vaccine.

The data confirm that the vaccine is effective in preventing symptomatic SARS-CoV-2 infection, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. The data show that two weeks after the second vaccine dose, the vaccine effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease, and death. The analysis found that the vaccine was 94% effective against asymptomatic SARS-CoV-2 infections.

The data were derived from de-identified aggregate Israel Ministry of Health surveillance data collected between January 17 and March 6, 2021, a time when the B.1.1.7 variant was the predominant strain in the country.

Following the authorization for emergency use of the Pfizer-BioNTech COVID-19 vaccine in Israel on December 6, 2020, the Israel Ministry of Health launched a national vaccination program targeting individuals age 16 years or older -- a total of 6.4 million people, representing 71% of the population. Israel regularly collects comprehensive, real-time data on SARS-CoV-2 testing, COVID-19 cases, including date of symptom onset, and vaccination history, through a nationally notifiable disease registry and the national medical record database.

In January, Pfizer and the Israel Ministry of Health entered into a collaboration agreement to monitor the real-world effect of the COVID-19 vaccine. The organizations plan to submit the data to a peer-reviewed journal.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here